Based on the aTyr Pharma, Inc. stock forecast from 1 analysts, the average analyst target price for aTyr Pharma, Inc. is USD 16.00 over the next 12 months. aTyr Pharma, Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of aTyr Pharma, Inc. is Very Bearish, which is based on 0 positive signals and 2 negative signals. At the last closing, aTyr Pharma, Inc.’s stock price was USD 3.45. aTyr Pharma, Inc.’s stock price has changed by +11.29% over the past week, -6.76% over the past month and 0% over the last year.
No recent analyst target price found for aTyr Pharma, Inc.
No recent average analyst rating found for aTyr Pharma, Inc.
Company Overview aTyr Pharma, Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. Read Less
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pul...Read More
Frequently Asked Questions About aTyr Pharma, Inc. (ATYR) Stock
Based on ratings from 1 analysts aTyr Pharma, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATYR's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ATYR is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on ATYR's stock to indicate if its overvalued.
The last closing price of ATYR's stock was USD 3.45.
The most recent market capitalization for ATYR is USD 0.14B.
Based on targets from 1 analysts, the average taret price for ATYR is projected at USD 16.00 over the next 12 months.
This means that ATYR's stock price may go up by +363.77% over the next 12 months.
We can't find any ETFs which contains aTyr Pharma, Inc.'s stock.
As per our most recent records aTyr Pharma, Inc. has 0 Employees.
aTyr Pharma, Inc.'s registered address is 10240 Sorrento Valley Road, San Diego, CA, United States, 92121.
You can get more information about it from aTyr Pharma, Inc.'s website at https://www.atyrpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About aTyr Pharma, Inc. (ATYR) Stock
Based on ratings from 1 analysts aTyr Pharma, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATYR's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ATYR is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on ATYR's stock to indicate if its overvalued.
The last closing price of ATYR's stock was USD 3.45.
The most recent market capitalization for ATYR is USD 0.14B.
Based on targets from 1 analysts, the average taret price for ATYR is projected at USD 16.00 over the next 12 months.
This means that ATYR's stock price may go up by +363.77% over the next 12 months.
We can't find any ETFs which contains aTyr Pharma, Inc.'s stock.
As per our most recent records aTyr Pharma, Inc. has 0 Employees.
aTyr Pharma, Inc.'s registered address is 10240 Sorrento Valley Road, San Diego, CA, United States, 92121.
You can get more information about it from aTyr Pharma, Inc.'s website at https://www.atyrpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATYR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
